Prophylaxis and management of adverse events associated with datopotamab deruxtecan

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Antibody-drug conjugates are a class of drugs designed to deliver highly effective cytostatic agents directly to tumor cells, thereby reducing their systemic effects and associated toxicity. One representative of this class is datopotamab deruxtecan (Dato-DXd), which is a conjugate of a monoclonal antibody with a cytostatic agent (topoisomerase I inhibitor) targeting trophoblast cell surface antigen 2 – a receptor widely expressed in non-small cell lung cancer, breast cancer and other solid tumors. Dato-DXd was first approved in Japan at the end of 2024 and then in the Russian Federation at the beginning of 2025. As is well known, the key to the successful use of any innovative drug is knowledge of its safety profile and management of adverse events. In this review, we present data on AEs observed in clinical trials of Dato-DXd, necessary preventive measures, and current recommendations for their diagnosis and treatment.

About the authors

Oleg A. Gladkov

Medical center EVIMED

Author for correspondence.
Email: gladkovoa@gmail.com
ORCID iD: 0000-0003-1367-2079
Russian Federation, 9v Blyuchera St., Chelyabinsk 454048

Albina S. Zhabina

Saint Petersburg Clinical Research and Practical Centre for Specialized Types of Medical Care (Oncological); N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

Email: gladkovoa@gmail.com
ORCID iD: 0000-0001-9749-8519
Russian Federation, 68a, lit. A, Leningradskaya St., Pesochny, Saint Petersburg 197758; 68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

Lyubov Yu. Vladimirova

National Medical Research Centre for Oncology

Email: gladkovoa@gmail.com
ORCID iD: 0000-0003-4236-6476
Russian Federation, 63 14th liniya St., Rostov-on-Don 344037

References

  1. Marei H.E., Cenciarelli C., Hasan A. Potential of antibody-drug conjugates (ADCs) for cancer therapy. Cancer Cell Int 2022;22:255. doi: 10.1186/s12935-022-02679-8
  2. Dean A.Q., Luo S., Twomey J.D., Zhang B. Targeting cancer with antibody-drug conjugates: Promises and challenges. MAbs 2021;13:1951427. doi: 10.1080/19420862.2021.1951427
  3. General characteristics of the medicinal product DATROWAY (lyophilizate for the preparation of a concentrate for solution for infusion, 100 mg). Registration certificate: LP-№(008970)-(RG-RU)-210225 dated 21.02.2025 (reissued on 23.12.2025). Available at: https://storage.yandexcloud.net/sb-prod-astrazeneca-static-01/api/media/Datroway_OKhLP.pdf (In Russ.).
  4. General characteristics of the medicinal product ENHERTU (lyophilizate for the preparation of a concentrate for solution for infusion, 100 mg) 14.05.2024. Registration certificate: LP-№(001242)-(РГ-RU) 21.09.2022 (reissued on 12.10.2023). Available at: https://storage.yandexcloud.net/sb-prod-astrazeneca-static-01/api/media/Enhertu_OKhLP.pdf (In Russ.).
  5. General characteristics of the medicinal product KADCYLA (lyophilizate for the preparation of a concentrate for solution for infusion, 100 or 160 mg) 12.08.2025. Registration certificate: LP-№(000832)-(РГ-RU) 25.05.2022. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/ЛП-_N_000832_-_РГ-RU_/InstrImg_2025_09_12_1521359/5d1531f2-24cc-4cc7-8944-c403f7ca3c91.pdf (In Russ.).
  6. Nguyen T.D., Bordeau B.M., Balthasar J.P. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers (Basel) 2023;15(3):713. doi: 10.3390/cancers15030713
  7. Suzuki Y., Zhou S., Ota Y. et al. Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis. JNCI Cancer Spectr 2023;7(5):pkad069. doi: 10.1093/jncics/pkad069
  8. Inamura K., Yokouchi Y., Kobayashi M. et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget 2017;8:28725–35. DOI: 10.18632/ oncotarget.15647
  9. Sakach E., Sacks R., Kalinsky K. Trop-2 as a Therapeutic target in breast cancer. Cancers 2022;14:5936. doi: 10.3390/cancers14235936
  10. Ambrogi F., Fornili M., Boracchi P. et al. Trop-2 is a determinant of breast cancer survival. PLoS One 2014;9:e96993. doi: 10.1371/journal.pone.0096993
  11. Okajima D., Yasuda S., Maejima T. et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther 2021;20:2329–40. doi: 10.1158/1535-7163.Mct-21-0206
  12. Shimizu T., Sands J., Yoh K. et al. First-in-human, phase i dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol 2023;41:4678–87. doi: 10.1200/JCO.23.00059
  13. Ahn M.J., Lisberg A., Goto Y. et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC. J Thorac Oncol 2025;20(11):1669–82. doi: 10.1016/j.jtho.2025.06.002
  14. Bardia A., Jhaveri K., Im S.A. et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol 2025;43(3):285–96. doi: 10.1200/JCO.24.00920
  15. Pistilli B., Jhaveri K., Im S.A. et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study. Ann Oncol 2025:S0923-7534(25)06337-9. doi: 10.1016/j.annonc.2025.12.017
  16. Dent R., Shao Z., Schmid P. et al. [oral presentation]. First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase 3 TROPION-Breast02 trial. Presented at: European Society of Medical Oncology Annual Meeting; October 17–21, 2025; Berlin, Germany; Abstract LBA21.
  17. A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I–III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03). ClinicalTrials.gov; 2026 [updated December 19, 2025; quoted February 4, 2026]. Available at: https://clinicaltrials.gov/study/NCT05629585.
  18. Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07). ClinicalTrials.gov; 2026 [updated January 12, 2025; quoted February 4, 2026]. Available at: https://clinicaltrials.gov/study/NCT05555732
  19. Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08). ClinicalTrials.gov; 2026 [updated January 7, 2026; quoted on February 4, 2026]. Available at: https://clinicaltrials.gov/study/NCT05215340
  20. Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03). ClinicalTrials.gov; 2026 [updated July 11, 2025; quoted February 4, 2026]. Available at: https://clinicaltrials.gov/study/NCT05489211
  21. Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR). ClinicalTrials.gov; 2026 [updated December 10, 2025; quoted February 4, 2026]. Available at: https://clinicaltrials.gov/study/NCT05687266
  22. Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14). ClinicalTrials.gov; 2026 [updated November 17, 2025; quoted February 4, 2026]. Available at: https://clinicaltrials.gov/study/NCT06350097.
  23. A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15). ClinicalTrials.gov; 2026 [updated January 9, 2026; quoted February 4, 2026]. Available at: https://clinicaltrials.gov/study/NCT06417814
  24. Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma. ClinicalTrials.gov; 2026 [updated January 30, 2026; quoted February 4, 2026]. Available at: https://clinicaltrials.gov/study/NCT07129993?intr=datopotamab%20deruxtecan&aggFilters=phase:3&rank=4
  25. Huang J., Huang T., Guo J. et al. The efficacy and safety of datopotamab deruxtecan (Dato-DXd) in advanced solid tumors: a systematic review and meta-analysis. Eur J Med Res 2025;30(1):1265. doi: 10.1186/s40001-025-03538-8
  26. Brown T.J., Gupta A. Management of cancer therapy-associated oral mucositis. JCO Oncol Pract 2020;16:103–19. doi: 10.1200/JOP.19.00652
  27. Basile D., Di Nardo P., Corvaja C. et al. Mucosal injury during anti-cancer treatment: from pathobiology to bedside. Cancers (Basel) 2019;11(6):857. doi: 10.3390/cancers11060857
  28. Lu Y., Patel K., Li H. et al. Exposure-response analysis of stomatitis associated with Datopotamab Deruxtecan, a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer [Poster W-001] American Conference on Pharmacometrics, 2023.
  29. Heist R.S., Sands J., Bardia A. et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. doi: 10.1016/j.ctrv.2024.102720
  30. A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator’s Choice of Chemotherapy in Participants with Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Who Have Been Treated with One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01): Clinical Study Protocol. Version 5.0. AstraZeneca; 2023. Available at: https://s3.amazonaws.com/ctr-med-7111/D9268C00001/1ad6cc6b-d845-4b62-8243-638bb9d24742/b9df981b-dd52-4380-b847-3f8b1ae10f10/CSP_redacted-v1.pdf
  31. Phase 3 Randomized Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-Lung01): Clinical Study Protocol. Version 5.0. Daiichi Sankyo. Inc.; 2023. Access date: 08.12.2025. Available at: https://ascopubs.org/action/downloadSupplement?doi=10.1200%2FJCO-24-01544&file=protocol_JCO-24-01544.pdf
  32. Lisberg A., Huppert L.A., Halmos B. et al. Datopotamab deruxtecan-associated select adverse events: clinical practices and institutional protocols on prophylaxis, monitoring, and management. Oncologist 2025;30(9):oyaf225. doi: 10.1093/oncolo/oyaf225
  33. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
  34. Semiglazova T.Yu., Belyak N.P., Vladimirova L.Yu. et al. Mucositis. RUSSCO Clinical Guidelines, Part 2. Zlokachestvennye opukholi = Malignant Tumours 2025;15(3s2):352–64. doi: 10.18027/2224-5057-2025-15-3s2-2-18
  35. Bader A., Begemann M., Al-Obaidi A. et al. Ocular complications of antineoplastic therapies. Future Sci OA 2023;9:FSO871. doi: 10.2144/fsoa-2022-0081
  36. Eaton J.S., Miller P.E., Mannis M.J., Murphy C.J. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther 2015;31:589–604. doi: 10.1089/jop.2015.0064
  37. American Optometric Association. Dry eye. Aoa.org; 2026.[updated January 12, 2026; quoted February 4, 2026]. Available at: https://www.aoa.org/healthy-eyes/eye-and-vision-conditions/ dry-eye?sso=y
  38. American Optometric Association. Keratitis. Aoa.org; 2026. [updated January 12, 2026; quoted February 4, 2026]. Available at: https://www.aoa.org/healthy-eyes/eye-and-vision-conditions/keratitis?sso=y
  39. Messmer E.M. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int 2015;112:71–81. doi: 10.3238/arztebl.2015.0071
  40. Renouf D.J., Velazquez-Martin J.P. et al. Ocular toxicity of targeted therapies. J Clin Oncol 2012;30:3277–86. DOI:10.1200/ JCO.2011.41.5851
  41. Tarantino P., Ricciuti B., Pradhan S.M., Tolaney S.M. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol 2023;20:558–76. doi: 10.1038/s41571-023-00783-w
  42. Stepan L.P., Trueblood E.S., Hale K. et al. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem 2011;59:701–10. doi: 10.1369/0022155411410430
  43. Girard N., Okamoto I., Lisberg A. et al. Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC) – nonsquamous (NSQ) histology in the Phase 3 TROPION-Lung01 trial. Poster presented at: European Lung Cancer Congress; March 20–23, 2024; Prague, Czech Republic.
  44. Jhaveri K., Bardia A., Im S.-A. et al. LBA2 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC): additional safety analysis from TROPION-Breast01. ESMO Open 2024;9:103479. doi: 10.1016/j.esmoop.2024.103479
  45. Conte P., Ascierto P.A., Patelli G. et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open 2022;7:100404. doi: 10.1016/j.esmoop.2022.100404
  46. Long K., Suresh K. Pulmonary toxicity of systemic lung cancer therapy. Respirology 2020;25(Suppl 2):72–9. doi: 10.1111/resp.13915
  47. Swain S.M., Nishino M., Lancaster L.H. et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd) – related interstitial lung disease/pneumonitis – Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 2022;106:102378. DOI: 10.1016/j. ctrv.2022.102378
  48. Muller N.L., White D.A., Jiang H., Gemma A. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer 2004;91(Suppl 2):24–30. doi: 10.1038/sj.bjc.6602064
  49. Kumagai K., Aida T., Tsuchiya Y. et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci 2020;111:4636–45. doi: 10.1111/cas.14686
  50. Cereser L., Della Rossa S., Sparascio F. et al. Chest computed tomography of trastuzumab-deruxtecan (T-DXd)-related interstitial lung disease: Key points for radiologists. Eur J Radiol 2026;194:112499. doi: 10.1016/j.ejrad.2025.112499
  51. Zhabina A. S., Trushenko N. V., Tyurin I. E. et al. Drug-induced interstitial lung diseases. RUSSCO clinical guidelines, part 2. Zlokachestvennye opukholi = Malignant tumours 2025;15(3s2): 330–51. (In Russ.). doi: 10.18027/2224-5057-2025-15-3s2-2-17
  52. Vladimirova L.Yu., Gladkov O.A., Koroleva I.A. et al. Nausea and vomiting. RUSSCO clinical guidelines, part 2. Zlokachestvennye opukholi = Malignant tumours 2025;15(3s2): 33–49. (In Russ.). doi: 10.18027/2224-5057-2025-15-3s2-2-02
  53. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Antiemesis. Version: 2.2025. Updated on May 12, 2025. Available at: https://www.nccn.org/professionals/ physician_gls/pdf/antiemesis.pdf
  54. Rombouts M.D., Swart E.L., VAN DEN Eertwegh A.J.M., Crul M. Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment. Anticancer Res 2020;40:1201–18. DOI: 10.21873/ anticanres.14062
  55. Rosello S., Blasco I., Garcia Fabregat L. et al. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Ann Oncol 2017;28(suppl_4):iv100–18. DOI: 10.1093/ annonc/mdx216
  56. Thompson L.M., Eckmann K., Boster B.L. et al. Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. Oncologist 2014;19:228–34. doi: 10.1634/theoncologist.2013-0286
  57. Horita N., Miyagi E., Mizushima T. et al. Severe anaphylaxis caused by intravenous anti-cancer drugs. Cancer Med 2021;10:7174–83. doi: 10.1002/cam4.4252
  58. Lemieux J., Maunsell E., Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 2008;17:317–28. doi: 10.1002/pon.1245
  59. Ahn M.J., Tanaka K., Paz-Ares L. et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol 2025;43(3):260–72. doi: 10.1200/JCO-24-01544
  60. Prieto-Callejero B., Rivera F., Fagundo-Rivera J. et al. Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer. Medicine (Baltimore) 2020;99:e21695. doi: 10.1097/MD.0000000000021695
  61. Ho M.Y., Mackey J.R. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res 2014;6:253–9. doi: 10.2147/CMAR.S40601
  62. Latipova D.Kh., Andreev V.V., Maslova D.A. et al. Neurological complications. RUSSCO clinical guidelines, part 2. Zlokachestvennye opukholi = Malignant tumours 2025;15(3s2): 410–25. (In Russ.). doi: 10.18027/2224-5057-2025-15-3s2-2-22

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 ABV-Press

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-86325 от  11.12.2023.